ParaguayTuberculosis profile
Population  2014 6.6 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.19 (0.16–0.23) 2.9 (2.4–3.5)
Mortality (HIV+TB only) 0.053 (0.042–0.065) 0.81 (0.64–1)
Prevalence  (includes HIV+TB) 3.6 (1.7–6.2) 55 (27–94)
Incidence  (includes HIV+TB) 2.8 (2.7–3) 43 (41–45)
Incidence (HIV+TB only) 0.29 (0.27–0.32) 4.5 (4.1–4.9)
         
Case detection, all forms (%) 80 (76–84)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.3 (0–1.7) 15 (6.1–28)
MDR-TB cases among notified pulmonary
TB cases
6 (0–31) 55 (23–100)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 1 371   163
Pulmonary, clinically diagnosed 459   42
Extrapulmonary 209   4
       
Total new and relapse 2 248    
Previously treated, excluding relapses 169    
Total cases notified 2 417    
Among 2 248 new and relapse cases:
187 (8%) cases aged under 15 years; male:female ratio: 2.2
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 308 (22%) 149 (39%) 457
Laboratory-confirmed RR-/MDR-TB cases     11
Patients started on MDR-TB treatment ***     13
TB/HIV 2014 Number (%)
TB patients with known HIV status 1 902 (79)
HIV-positive TB patients 190 (10)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 114 (60)
HIV-positive TB patients on antiretroviral therapy (ART) 165 (87)
HIV-positive people screened for TB 669  
HIV-positive people provided with IPT 0  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (68) 2 257
Previously treated cases, excluding relapse, registered in 2013 (48) 162
HIV-positive TB cases, all types, registered in 2013 (34) 181
RR-/MDR-TB cases started on second-line treatment in 2012 (57) 7
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 2.0
Culture (per 5 million population) 9.9
Drug susceptibility testing (per 5 million population) 0.8
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions) 23
% Funded domestically 17%
% Funded internationally 3%
% Unfunded 81%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-31 Data: www.who.int/tb/data